This content is machine translated Chronic inflammatory bowel disease The combination for a better outcome Current therapeutic strategies for inflammatory bowel disease (IBD) have reached a plateau in terms of response and/or remission rates achieved with a single therapeutic agent. Consequently, advanced combination therapy (ACT)…
View Post 5 min This content is machine translated Biologics for IBD Therapy break – what speaks for and against it In the treatment of chronic inflammatory bowel disease (IBD), effective control of inflammation is fundamental, and an early switch to novel therapies to avoid long-term complications is also emphasized in…
View Post 6 min This content is machine translated IBD in children and adolescents Calprotectin concentration and PUCAI score are indicative The prevalence of chronic inflammatory bowel diseases (IBD) such as Crohn’s disease (MC) and ulcerative colitis (UC) has also been increasing in recent years.in the age groups of children and…
View Post 5 min This content is machine translated Crohn's disease Therapy selection and treatment sequences In recent years, the treatment spectrum for patients with inflammatory bowel disease (IBD) has expanded significantly. Based on the recognition that chronic and untreated inflammation adversely affects disease progression, early…
View Post 13 min This content is machine translated Chronic inflammatory bowel disease Treatment options for vulnerable patient populations Vulnerable patient populations with inflammatory bowel disease (IBD) require individualized and advanced treatment options. For example, the proportion of childless individuals with IBD is increased, often due to inadequate information… CME-Test
View Post 4 min This content is machine translated Chronic inflammatory bowel disease (CED) Vedolizumab in subcutaneous formulation proves its worth in everyday practice That vedolizumab in the maintenance treatment of IBD shows comparable efficacy when administered subcutaneously to intravenous administration has been demonstrated several times. Patients can thus carry out the treatment independently…
View Post 9 min This content is machine translated "IBD matters" Extraintestinal manifestations of inflammatory bowel diseases (IBD) The leading symptoms of inflammatory bowel disease (IBD) are chronic diarrhea (>4 weeks), abdominal pain, bloody stools, and rapid weight loss. IBD is often relapsing, with active phases alternating with… CME-Test
View Post 4 min This content is machine translated Chronic inflammatory bowel disease (CED) Position paper on the current use of SARS-CoV-2 vaccines. The Swiss Research and Communication Network on Inflammatory Bowel Disease (IBD-net) recommends that all patients with inflammatory bowel disease (IBD) should be vaccinated against SARS CoV-2. This assessment is based…
View Post 4 min This content is machine translated Chronic inflammatory bowel disease (CED) Two new biomarkers identified for targeted therapy Surrogate markers have an important role in the disease management of IBD. Researchers found evidence that microbial butyrate synthesis may predict therapeutic efficacy and thus play an important role in…
View Post 10 min This content is machine translated Chronic inflammatory bowel disease (CED) Modern “State-of-the-Art” Pharmacotherapy – an Update Modern approaches to the treatment of inflammatory bowel disease (IBD) are based on the motto “treat-to-target”, whereby in addition to symptom relief and induction of disease remission, the aim nowadays… CME-Test
View Post 3 min This content is machine translated Chronic inflammatory bowel disease (CED) Calprotectin as a therapy-relevant inflammatory marker Empirical findings show that calprotectin is the most important laboratory parameter for diagnosis as well as for monitoring the disease and therapy adjustments during its course. The treatment goal of…
